🚀 VC round data is live in beta, check it out!
Damora Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Damora Therapeutics
Damora Therapeutics Overview
About Damora Therapeutics
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Founded
2019
HQ
Employees
5
Website
Financials (FY)
EV
$2B
Damora Therapeutics Financials
Damora Therapeutics reported last fiscal year revenue of — and negative EBITDA of ($211M).
In the same fiscal year, Damora Therapeutics generated ($211M) in EBITDA losses and had net loss of ($210M).
Damora Therapeutics P&L
In the most recent fiscal year, Damora Therapeutics reported revenue of — and EBITDA of ($211M).
Damora Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($211M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($210M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Damora Therapeutics Stock Performance
Damora Therapeutics has current market cap of $2B, and enterprise value of $2B.
Damora Therapeutics' stock price is $29.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-3.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDamora Therapeutics Valuation Multiples
Damora Therapeutics trades at (8.5x) EV/EBITDA.
Damora Therapeutics Financial Valuation Multiples
As of March 29, 2026, Damora Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate Damora Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Damora Therapeutics has a P/E ratio of (8.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (8.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (8.5x) | XXX | XXX | XXX |
| P/E | — | XXX | (8.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (265.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Damora Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Damora Therapeutics Margins & Growth Rates
Damora Therapeutics' revenue in the last fiscal year grew by —.
Damora Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 899% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Damora Therapeutics Public Comps
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Damora Therapeutics M&A Activity
Damora Therapeutics acquired XXX companies to date.
Last acquisition by Damora Therapeutics was on XXXXXXXX, XXXXX. Damora Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Damora Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDamora Therapeutics Investment Activity
Damora Therapeutics invested in XXX companies to date.
Damora Therapeutics made its latest investment on XXXXXXXX, XXXXX. Damora Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Damora Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Damora Therapeutics
| When was Damora Therapeutics founded? | Damora Therapeutics was founded in 2019. |
| Where is Damora Therapeutics headquartered? | Damora Therapeutics is headquartered in Denmark. |
| How many employees does Damora Therapeutics have? | As of today, Damora Therapeutics has over 5 employees. |
| Who is the CEO of Damora Therapeutics? | Damora Therapeutics' CEO is Sherwin Sattarzadeh. |
| Is Damora Therapeutics publicly listed? | Yes, Damora Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Damora Therapeutics? | Damora Therapeutics trades under DMRA ticker. |
| When did Damora Therapeutics go public? | Damora Therapeutics went public in 2020. |
| Who are competitors of Damora Therapeutics? | Damora Therapeutics main competitors are |
| What is the current market cap of Damora Therapeutics? | Damora Therapeutics' current market cap is $2B. |
| Is Damora Therapeutics profitable? | No, Damora Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.